Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation

  • Tamara Seredenina ,

    Contributed equally to this work with: Tamara Seredenina, Ozgun Gokce

    Affiliation Laboratory of Functional Neurogenomics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

  • Ozgun Gokce ,

    Contributed equally to this work with: Tamara Seredenina, Ozgun Gokce

    Affiliation Laboratory of Functional Neurogenomics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

  • Ruth Luthi-Carter

    Affiliation Laboratory of Functional Neurogenomics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation

  • Tamara Seredenina, 
  • Ozgun Gokce, 
  • Ruth Luthi-Carter



The molecular phenotype of Huntington's disease (HD) is known to comprise highly reproducible changes in gene expression involving striatal signaling genes. Here we test whether individual changes in striatal gene expression are capable of mitigating HD-related neurotoxicity.

Methodology/Principal Findings

We used protein-encoding and shRNA-expressing lentiviral vectors to evaluate the effects of RGS2, RASD2, STEP and NNAT downregulation in HD. Of these four genes, only RGS2 and RASD2 modified mutant htt fragment toxicity in cultured rat primary striatal neurons. In both cases, disease modulation was in the opposite of the predicted direction: whereas decreased expression of RGS2 and RASD2 was associated with the HD condition, restoring expression enhanced degeneration of striatal cells. Conversely, silencing of RGS2 or RASD2 enhanced disease-related changes in gene expression and resulted in significant neuroprotection. These results indicate that RGS2 and RASD2 downregulation comprises a compensatory response that allows neurons to better tolerate huntingtin toxicity. Assessment of the possible mechanism of RGS2-mediated neuroprotection showed that RGS2 downregulation enhanced ERK activation. These results establish a novel link between the inhibition of RGS2 and neuroprotective modulation of ERK activity.


Our findings both identify RGS2 downregulation as a novel compensatory response in HD neurons and suggest that RGS2 inhibition might be considered as an innovative target for neuroprotective drug development.


Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by a CAG repeat expansion mutation encoding an abnormally long polyglutamine tract in the huntingtin (htt) protein [1]. Accumulation of mutant htt and its polyglutamine-containing fragments subsequently manifests as nuclear htt enrichment and the formation of intracellular inclusion bodies in neurons of the striatum and cortex, the cells that eventually degenerate in HD [2], [3], [4]. Mutant htt attacks multiple cellular processes crucial for neuronal function [5]; these include transcriptional regulation, energy metabolism, neurotransmission, and axonal transport. One of the earliest detectable effects of mutant htt in the brain is the downregulation of striatal signaling genes [6], [7], [8]. The dysregulated genes notably include multiple components of G-protein-coupled receptor (GPCR) signaling cascades, a finding confirmed in multiple lines of mutant htt-expressing mice [9] and human HD brain [10].

A number of different mechanisms have been proposed to explain HD-induced alterations in gene expression [11]. These draw from evidence that mutant htt interacts with and can disrupt the activities of a large number of transcriptional regulatory proteins. The implicated proteins include DNA-binding transcription factors, transcriptional co-regulators, histone-modifying enzymes, and the basal transcription machinery [11], [12]. The relative contributions of various transcriptional abnormalities as important drivers of the disease process are still under active investigation.

A lesser-explored perspective on altered gene expression in HD is the extent to which differentially expressed genes participate in modulating htt toxicity. While it has been widely assumed that transcriptomic changes reflect direct consequences of mutant htt on gene regulation, this is far from being proven. In fact, some gene expression changes may instead reflect the neuron's activation of autocompensatory mechanisms to counteract mutant htt toxicity [13]. Consistent with this notion, gene expression changes are not uniformly reversed in parallel with the modulation of HD phenotype [14], [15], [16]. In the present study, we sought to identify compensatory HD-related gene expression changes to elucidate novel ways to promote neuronal viability.

Here we identify regulator of G-protein signaling 2 (RGS2) as a novel modifier in primary striatal neuron models of HD. The RGS family of proteins consists of over 30 members characterized by the presence of a conserved ∼120 aa RGS domain necessary and sufficient for binding Gα subunits of heterotrimeric G proteins. RGS2 acts as an attenuator of signal transduction for GPCRs via enhancement of the rate of hydrolysis of GTP to GDP by Gαq [17] and Gαi subunits [18], [19]. RGS2 also interacts directly with adenylyl cyclases 3 and 5 [20], [21] to inhibit the synthesis of cAMP, and modulates MAPK signaling [18], [22].

In addition to identifying RGSs as a possible point of intervention to combat striatal neurodegeneration in HD, the present results suggest that the current view of HD-related effects on neuronal gene expression needs to better account for pro-survival autocompensatory responses.


The aim of the present study was to identify HD-regulated genes that might function as HD modifiers. We selected genes of interest based on microarray gene expression data from HD brain and HD model systems. A simple meta-analysis of data obtained from human HD brain [10], mouse models of HD [9] and a primary neuron model of HD (PGK-htt171-82Q; [23]) allowed us to choose genes whose expression was decreased in all 3 systems (Table 1). We further narrowed our selection of genes to those that were known or suspected to participate in important striatal neuron signaling processes. The following candidates were subsequently chosen for functional testing.

Table 1. Expression of potential gene modifiers in different HD models and in human HD brain.

a) Striatum-enriched phosphatase (STEP/Ptpn5): STEP is a striatal neuron-enriched tyrosine phosphatase whose activity is responsive to glutamatergic and dopaminergic afferents [24], [25], [26]. Reciprocally, STEP activation has been shown to negatively regulate NMDA receptor stimulation via dephosphorylating and promoting the endocytosis of the NMDA receptor subunit NR2B [27].

b) Ras homolog enriched in striatum (Rhes/RASD2): RASD2 is a member of the large ras superfamily of proteins [28], [29]. Interestingly RASD2 knockout mice show a motor coordination deficit [30] and therefore somewhat resemble HD model animals. Moreover, RASD2 plays an important role in regulating dopamine receptor signaling [31], a neurotransmitter system known to be affected in HD [32], [33].

c) RGS2 is known to be an important regulator of Gαq subunit and Gαi -containing heterotrimeric G-proteins, and adenylyl cyclases [20], [34]. G-protein-coupled receptor signaling and cAMP signaling has been shown in previous studies to be significantly abnormal in HD [7], providing a rationale for testing the ability of RGS2 to compensate for such deficiencies.

d) Neuronatin (NNAT) is expressed during brain development and is believed to regulate neuronal differentiation [35]. Previous data in the neuron-like PC12 cell line suggests potential neuroprotective effects of NNAT [36], leading us to hypothesize that it might do the same in HD model systems.

We first used qPCR to assess differential expression of the above genes in the TRE-htt171-82Q model of HD [37]. As expected based on HD mouse studies, the qPCR results show progressive decreases in STEP, RASD2, RGS2 and NNAT RNAs in TRE-htt171-82Q compared to TRE-htt171-18Q cells (Fig. 1).

Figure 1. Timecourse of differential expression in the TRE-htt171-82Q primary striatal lentiviral model of HD.

RGS2, RASD2, NNAT and STEP RNA levels were measured by qPCR in primary striatal cells expressing mutant htt fragments under the control of a TRE promoter. Target RNA levels (i.e those of RGS2, RASD2, NNAT, STEP) were normalized to the expression level of β-actin and expressed as % control relative to neurons expressing htt171-18Q at the corresponding time point. (mean±SEM); n = 4. * p<0.05; ** p<0.01; *** p<0.001.

We next tested whether restoring the expression of these genes modified the survival of htt171-82Q-exposed cells. For these experiments, we implemented a primary striatal lentiviral model of HD described previously [37]. As expected, lentivirus-mediated expression of htt171-82Q resulted in a ∼50% decrease in NeuN-positive (neuronal) cells as compared to control cells expressing htt171-18Q (Fig. 2). Co-expression of NNAT or STEP with htt171-82Q did not influence htt toxicity, suggesting that these genes do not have a major disease-modifying effect. In contrast, the expression of RGS2 and RASD2 decreased the viability of neurons expressing either htt171-18Q or htt171-82Q. In order to rule out non-specific viral toxicity as an explanation for the observed effects, we repeated the experiments with independent batches of lentiviral vectors (not shown) and lower vector concentrations (8 ng/ml or 2.5 ng/ml p24 antigen; Fig. 3). These experiments showed that under conditions nontoxic to htt171-18Q cells, both RGS2 and RASD2 still enhanced the toxicity of htt171-82Q. These data indicate that RGS2 and RASD2 may exacerbate HD-related neurotoxicity.

Figure 2. Effects of restoring downregulated RNAs in the TRE-htt171-82Q primary striatal model of HD.

Primary striatal neurons were infected on DIV1 with lentiviral vectors encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4 with vectors encoding RGS2, RASD2, NNAT, STEP or CFP (control) at a concentration of 25 ng p24 antigen/ml. Neuronal viability was assessed after 3 weeks in culture by quantification of NeuN-positive cells. * indicates significance of mutant htt effects; + indicates significance of effects of the candidate modifier expression. Data are presented as mean±SEM, n = 15, expressed as % control (relative to WT htt171-18Q+CFP). * p<0.05; ** p<0.01; *** p<0.001.

Figure 3. Effects of candidate modifiers at lower expression levels in the TRE-htt171-82Q primary striatal neuron model of HD.

Primary striatal neurons were infected on DIV1 with lentiviral constructs encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4 with constructs encoding RGS2, RASD2, or CFP (control) at the concentration of 8 or 2.5 ng p24 antigen/ml. Neuronal viability was assessed after 3w in culture by quantification of NeuN-positive cells. * indicates significance of mutant htt effects; + indicates significance of effects of candidate modifier expression. Values are presented as mean±SEM, n = 15, expressed as % control (WT htt171-18Q+CFP). * p<0.05; ** p<0.01; *** p<0.001.

The above results suggested to us that decreasing levels of RGS2 and RASD2 might be beneficial to HD neurons. To investigate this hypothesis, we used RNAi to further decrease the expression of RGS2 and RASD2 in parallel with neuronal exposure to htt171-82Q. Lentivirally-delivered shRNAs resulted in effective silencing of both RGS2 and Rhes RNAs and proteins (Fig. 4A,B). Moreover, as predicted, the silencing of both genes protected against htt171-82Q toxicity (Fig. 4C).

Figure 4. Silencing of RGS2 or RASD2 is protective in the TRE-htt171-82Q primary striatal neuron model of HD.

A RGS2-targeting shRNA delivered via a lentiviral vector resulted in a 46.1±7.2% reduction of RGS2 mRNA (in neurons) and 40±5.4% reduction of RGS2 protein expression (in HEK 293T cells), respectively (Panel A). A RASD2-targeting shRNA resulted in a 76.8±0.3% reduction of RASD2 mRNA expression (in neurons) and 79.1±3.6% reduction of RASD2 protein expression (in HEK 293T cells), respectively (Panel B). Immunoblots were performed on HEK 293 cells expressing HA-tagged RGS2 and RGS2 silencing constructs. Lentiviral delivery of an shRNA targeting GFP (shGFP) was used as a control. Values are presented as mean±SEM, n = 3. * p<0.05; ** p<0.01; *** p<0.001. (Panel C). Primary striatal neurons were infected on DIV1 with lentiviral vectors encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4 with shRNA vectors targeting RGS2, RASD2, or GFP (control) at a concentration of of 1 ng p 24 antigen/ml. Neuronal viability was assessed by NeuN counting as described in Fig. 2.

Whereas a parallel study investigating the role of Rhes in pathogenesis of HD had recently been described [38] (discussed below), the mechanism of modulation of mutant htt toxicity by RGS2 expression was unknown. Therefore, we conducted additional experiments to address this question. We first assessed whether RGS2 expression had an effect on mutant htt levels or the formation of htt inclusions (Fig. 5). Co-expression of RGS2 with mutant htt again resulted in reduced neuronal survival compared to co-expression of mutant htt with CFP as control. Although the total number of mutant htt-positive nuclei was reduced when RGS2 was expressed, this did not represent a change in nuclear accumulation when corrected for neuronal number. Correspondingly, silencing of RGS2 in cells expressing mutant htt increased the number of surviving neurons and the number of nuclei carrying accumulated htt, but not the ratio. These results led us to conclude that modulation of htt toxicity by RGS2 expression levels is not due to a major change in the aggregation or accumulation of mutant htt.

Figure 5. Modulation of RGS2 expression does not influence nuclear accumulation of mutant htt.

Primary striatal neurons were infected on DIV1 with lentiviral constructs encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4 with an RGS2 expression vector as described in Fig. 2B (A) or RGS2 silencing construct as in Fig. 4B (B). NeuN-positive and 2B4-positive nuclei were quantified as described in the Methods section. (C) Top: representative images of NeuN and 2B4 staining; scale bar 100 µm. Bottom: Representative higher magnification images showing the continued presence of 2B4-positive nuclei after RGS2 silencing; scale bar  = 10 µm.

RGS2 acts as an attenuator of signal transduction for GPCRs via enhancement of the rate of GTP hydrolysis by Gαi [18], [19] which couples negatively to ACs. RGS2 has also been shown to interact directly with AC3 and AC5 to inhibit the synthesis of cAMP [20], [21], [39]. Importantly, cAMP signaling has been a proposed deficit in HD brain [40], [41], and AC5 is the prominent AC in striatum, the most affected HD brain region. We therefore tested the hypothesis that the reduced levels of RGS2 in HD might result in a compensatory restoration in cAMP levels which could explain the RGS2-mediated neuroprotective effect. We first assessed whether modulation of RGS2 expression would influence cAMP levels in striatal neurons in non-disease conditions (Fig. S1). However, neither overexpression nor silencing of RGS2 changed basal cAMP levels (as compared to CFP or shGFP controls, respectively). Stimulation of cAMP biosynthesis with the D1 receptor agonist SKF-82958 resulted in an expected increase in cAMP levels; however, this increase was not influenced significantly by the corresponding expression levels of RGS2 (Fig. S1). We then went on to test whether RGS2 silencing improves cAMP levels in htt171-82Q-exposed neurons. These experiments demonstrated no difference in cAMP level in neurons expressing htt171-82Q compared to htt171-18Q (Fig. 6); moreover, decreasing RGS2 expression was without effect on cAMP levels in either basal or stimulated conditions. We interpret these results to indicate that the protective effect of RGS2 silencing observed in our model is not explained by the modulation of cAMP biosynthesis.

Figure 6. RGS2 silencing does not influence cAMP levels in htt171-82Q-expressing primary striatal neurons.

Primary striatal neurons were exposed to htt171-18Q- or htt171-82Q-encoding vectors and RGS2 shRNA (or control GFP shRNA) as described in Fig. 4B. After 2.5 weeks in culture, levels of cAMP were measured in basal conditions and after stimulation with 10 µM SKF-82958 for 15 min. Data are presented as mean±SEM, n = 6.

We therefore considered other plausible mechanisms of RGS2-mediated neuroprotection. Previous experiments in COS-7 cells expressing M3 muscarinic receptors showed that RGS2 decreased the phosphorylation and activation of ERK1/2 [18], [22]. Since ERK1/2 activation is a previously implicated mediator of neuroprotection in HD models [42], [43], we tested the hypothesis that inhibiting RGS2 might also be effective by increasing ERK activity. Interestingly, RGS2-silenced cells exposed to mutant htt171-82Q demonstrated the hypothesized increase in ERK1/2 phosphorylation (Fig. 7); a non-statistically significant trend towards increased ERK phosphorylation (after normalization for ERK total protein levels) was also observed in Htt171-18Q cells (Fig. S2). Conversely, Akt phosphorylation was unaffected by RGS2 silencing (Fig. S3). Thus, we suggest that the enhancement of ERK signalling may be the mechanism responsible for the RGS2-silencing-induced neuroprotection.

Figure 7. RGS2 silencing increases ERK2 phosphorylation in neurons expressing mutant htt.

Primary striatal neurons were infected with htt171-82Q expression and RGS2 silencing vectors as described in Fig. 4B. After 2.5 weeks in culture, levels of ERK1/2 phosphorylation were measured by immunoblot. Data are presented as mean±SEM, n = 6, normalized to htt171-82Q+shGFP control. * p<0.05.

Since ERK activation has been shown to be neuroprotective in a number of contexts (for caveats, see Discussion), we also asked whether RGS2 might be able to modulate neurotoxicity due to mitochondrial stress. We therefore assessed its modulation of neuronal viability following exposure of striatal neurons to the mitochondrial toxin 3-nitropropionic acid (3NP). Whereas RGS2 overexpression decreased neuronal viability and enhanced 3NP toxicity, silencing RGS2 protected primary striatal neurons from these effects (Fig. 8). These results suggest that diminishing RGS2 activity may be neuroprotective against a number of toxic stimuli.

Figure 8. RGS2 levels modulate 3NP toxicity.

Primary striatal neurons were infected on DIV 4 with an RGS2 lentiviral expression vector at a concentration of 8 ng/ml p24 (A) or a lentiviral silencing construct targeting RGS2 at concentration of 1 ng/ml p24 (B). Vectors encoding CFP or shGFP were used as controls (in A and B, respectively). After 2 weeks in culture, neurons were treated with 100 or 300 uM 3NP. Neuronal viability was assessed after 48 h by NeuN counting.

Taken together with our previous findings regarding differential gene expression in HD brain, these results indicate that the downregulation of RGS2 and RASD2/Rhes expression comprise autoprotective neuronal responses, rather than etiologic events, in HD. Moreover, the data of the present study provide a novel rationale for exploring RGS modulation of intracellular signalling as a new possible avenue for the development of neuroprotective therapies.


In the present study, we investigated the functional consequences of disease-induced downregulation of the expression of several important striatally expressed genes. The continued evaluation of the downstream effects of HD-induced changes in gene regulation is important to better understand mechanisms of disease pathogenesis and also to identify novel therapeutic targets and pathways that can modulate the course of the disease. The latter is particularly important because no disease-modifying therapy for HD exists to date.

We show in this report that individual gene expression changes have different effects on HD progression, since restoring their expression levels does not uniformly modify mutant htt's effects. Previous studies by our group and others have also suggested that such heterogeneous effects might exist. For example, diminished hippocalcin levels were also shown not to account for sensitization to HD-related toxicities [37], similar to the results observed here for NNAT and STEP.

Importantly, however, we also define another subset of gene expression changes that appears to represent an autocompensatory neuronal response to mutant htt accumulation. One such HD-modifying compensatory response is the downregulation of RASD2/Rhes. An important parallel study implicating Rhes in the pathogenesis of HD was also published recently [38]. Our demonstration that reduction of RASD2/Rhes expression protects striatal neurons from mutant htt is thus concordant with these independently obtained results (in non-neuronal cells). Subramaniam et al. have further provided evidence that Rhes-enhanced sumoylation of mutant htt increases its cytotoxicity. An earlier study suggested that the expression of another striatally enriched gene, CalDAG-GEF1, might account for the brain regional selectivity of mutant htt toxicity [13], by demonstrating that the CalDAG-GEF1 is downregulated in HD human caudate and in R6/2 mice striatum and that silencing of this gene protects neurons from toxicity induced by mutant htt in an organotypic cortico-striatal slice model of HD. Although it is not possible to state for certain that the HD-affected neuron senses and actively compensates for mutant htt’s effects, the end results are clearly beneficial rather than etiologic.

In the present study we identified RGS2 as a novel modifier of HD neurotoxicity. The decreased RGS2 expression observed in HD also seems to be compensatory, since restoration of RGS2 expression enhances mutant htt toxicity, and downregulation of its expression conversely results in neuroprotection. The best-known function of RGS2 is its RGS-domain-mediated attenuation of GPCR-mediated signalling. Our interest in the RGS family of genes was peaked by previous findings that heterotrimeric GPCR signaling is significantly altered in HD [7], [10], [23]. We were somewhat surprised to observe that the modulation of cAMP levels was not a significant contributor to htt toxicity in our model system. However, the HD-induced changes in cAMP levels have been debated, and are likely to comprise a set of potentially complex and dynamic effects [44], [45], [46], [47]. Moreover, some effects attributed to deficient cAMP-related gene regulation invoke downstream steps of transcriptional activation [40], [41] rather than proximal signal transduction events.

We have not ruled out the possible role of RGS2 in regulating other GPCRs important for striatal function. We have determined, however, that negative regulation of RGS2 expression results in an increase in ERK2 phosphorylation that likely explains, at least in part, its neuroprotective effect. Although ERK’s effects on neurodegeneration in other conditions has been debated [48], [49], previous studies have been concordant in showing that ERK activation achieves neuroprotection against HD when ERK is regulated endogenously, regulated by small molecules, or activated via BDNF signaling [42], [43], [50], [51]

Our studies suggest that RGS2 antagonists might be an interesting area for development of anti-neurodegenerative disease therapeutics. This idea is further supported by the fact that RGS2 knock-out mice show increased survival of retinal ganglion cells [52]. However, other studies of RGS2 null-mutant animals suggest proceeding with caution. For example, hypertension and deficiencies in T-cell activation have been reported [53].

Intriguingly, the expression levels of other members of the RGS gene family are also changed in HD models and human HD brain [7], [10], [23]. Since these factors are also potentially important regulators of GPCR signaling, which is impaired in HD, other RGS family members function may also be an interesting subject of further investigation. This is particularly true since this family of proteins is generally considered amenable to small-molecule therapeutics.

Materials and Methods

Ethics Statement

All experiments were approved by the local veterinary office and the Commission for Animal Experimentation of the Canton of Vaud Switzerland, authorization number 1667.2 issued by the Service de la consommation et des affaires vétérinaires (SCAV)

Plasmid expression vectors and lentiviral production

Rat cDNAs encoding RGS2 (NM_053453.2), RASD2 (NM_133568.1), PTPN5 (NM_019253.3) and NNAT transcript variant 2 (NM_181687.1) were amplified from total rat brain cDNA using the polymerase chain reaction (PCR) and cloned into the shuttle plasmid pENTR/D-TOPO (Invitrogen, Carlsbad, CA, USA) using the pENTR Directional TOPO Cloning Kit (Invitrogen). The cDNAs were then transferred from the shuttle vector into a self-inactivating lentiviral plasmid vector with a woodchuck hepatitis virus posttranscriptional regulatory element (SIN-W) under the control of the mouse phosphoglycerate kinase 1 (PGK) promoter using Invitrogen's GatewayTM recombination technology. The same procedure was performed to clone an shRNA-generating construct targeting the rat RASD2 sequence AGAAGAACACGAACGUAAA (with UUCAAGAGA used as the loop sequence). An shRNA-generating construct for rat RGS2 was obtained from Sigma in a pLKO.1-puro vector (targeting sequence GATGAACTGCTGGCCAGTAAA (TRCN0000054762)).

Lentiviral vectors were produced in human embryonic kidney 293T (HEK293T) cells with a four-plasmid system as described previously [37]. The viruses were resuspended in PBS with 1% of BSA and the particle content was assessed by p24 antigen ELISA (RETROtek; Gentaur).

In vitro lentiviral model of Huntington's disease

Primary cultures of striatal neurons were prepared and infected at DIV1 with lentiviral vectors as described in [37]. Htt-expressing lentiviruses encoding the first 171 amino acids of wild-type or mutant human htt, (SIN-W-TRE-htt171-18/82Q, respectively) were applied at a particle concentration of 25 ng p24 antigen/ml culture medium together with a vector encoding the tetracycline-controlled transactivator tTA1 under the control of PGK promoter (at a concentration of 40 ng p24/ml). At DIV4 neurons were infected with lentiviral expression constructs for RGS2, RASD2, NNAT or PTPN5 (at a p24 concentration of 25 ng/ml or 8.3 ng/ml) or with lentiviral silencing constructs for RGS2 and RASD2 (at a p24 concentration of 1 ng/ml). Vectors expressing CFP or an shRNA targeting green fluorescent protein were used as controls for expression and silencing studies, respectively. Three weeks after the infection of htt constructs, cells were fixed and their survival assessed by NeuN counting [37].

3-Nitropropionic acid toxicity studies

Primary cultures of striatal neurons were prepared as in [37] and infected at DIV4 with lentiviral constructs for expression or silencing of indicated genes. At DIV17 cultures were treated with 100 or 300 uM 3-nitropropionic acid (3-NP). Forty-eight hours later cells were fixed and their survival assessed by NeuN-positive cell counting.


Cells were fixed in 4% paraformaldehyde for 20 min at RT, washed with PBS and blocked by incubation in PBS containing 10% normal goat serum (NGS, Gibco, Invitrogen, Basel, Switzerland) and 0.1% Triton X-100 (TX, Fluka, Sigma, Buchs, Switzerland). Cells were incubated with primary antibodies for 1h at RT (anti-Neuronal Nuclei (NeuN) (Chemicon MAB377 clone A60; 1∶500) or anti-huntingtin (Chemicon MAB5492 clone 2B4; 1∶500)), washed in PBS and incubated for 1 h at RT with fluorescent secondary antibody (Alexa-Fluor 488, A21121, Invitrogen; 1∶1000). Where indicated, nuclei were stained with Hoechst 33342 dye (Invitrogen, Basel, Switzerland). Images of NeuN-labeled cultures (n = 15 per condition) and of 2B4-labeled cultures (n = 6 per condition) were acquired using fully automated BD Pathway 855 (BD Biosciences, San Diego, USA) microscope under non-saturating exposure conditions, using the same acquisition settings for all samples in a given experiment. Counting of nuclei was performed with ImageJ software (NIH, Bethesda, MD, USA) applying intensity and size thresholds. Neurons with accumulation of htt in the nucleus as determined by 2B4 staining were counted as htt-accumulation positive.


Total RNA was extracted using the RNeasy kit (Qiagen) and 500 ng of total RNA were used for cDNA synthesis employing High Capacity cDNA RT kit (Applied Biosystems). Quantitative real-time PCR was performed on a 7900HT Real-Time PCR System with SDS 2.3 software (Applied Biosystems) using TaqMan Universal PCR Mastermix (Applied Biosystems). Relative expression (V) was calculated by normalization of gene expression to β-actin expression as described in [54]. All qPCR reactions were performed in triplicate. The following TaqMan assays obtained from Applied Biosystems were used: β-actin Rn00667869_m1; RGS2 Rn00584932; RASD2 Rn00592054; NNAT Rn00822063; PTPN5 Rn00570437_m1.

Statistical analyses

Numerical data represent the mean values ± SEM. The one-way ANOVA was used to compare multiple conditions and the two-tailed Student's t-test was used for two-group comparisons. p < 0.05 was set as the threshold for statistical significance.

cAMP assay

cAMP measurements were performed using the Direct cAMP ELISA kit (CA-200, Sigma-Aldrich), according to the protocol supplied by the manufacturer. Primary striatal cultures at 2.5 weeks in culture were stimulated with 10 µM Forskolin or 10 µM SKF-82958 for 15 min then harvested by direct lysis in 0.1 M HCl. The supernatant was recovered by centrifugation after which a small aliquot of lysate (10 µl) was used to determine protein concentration using the BCA protein assay (Pierce). The acetylation procedure was employed to increase assay sensitivity. cAMP measurements were normalized to total protein. A minimum of 4 samples per condition were assayed.

Immunoblot experiments

For analysis of phosphoproteins, primary striatal neurons were harvested in RIPA buffer (Sigma), containing protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktails 1 and 2 (Sigma) and PMSF 1 mM. Proteins were separated on 12% SDS-polyacrylamide gels and transferred to nitrocellulose membrane. Membranes were blocked for one hour in 30% Odyssey® Blocking Buffer in PBS (LI-COR Biosciences) followed by incubation with primary antibodies diluted in Blocking Buffer with 0.1% Tween-20 overnight at 4°C. Membranes were rinsed with 0.1% Tween-20/PBS followed by incubation with secondary antibody diluted in Blocking Solution for one hour at RT. After final rinses, blots were scanned with an Odyssey® Infrared Imager and densitometric measurements were obtained using Odyssey software (LI-COR Biosciences). For the detection of pERK1/2 images were acquired using ImageQuant LAS 4000 (GE Healthcare). Primary and secondary antibodies comprised: mouse anti-phospho-Erk1/2 (Millipore 05-481, 1∶1000), rabbit anti total ERK1/2 rabbit (Millipore 06-182, 1∶1000), rabbit anti-HA tag (Covance MMS-101R, 1∶2000), rabbit anti-a-tubulin (Abcam ab4074, 1∶2000), donkey anti-mouse IRDye 800CW (LI-COR Biosciences, 1∶15000), donkey anti-rabbit IRDye 680 (LI-COR Biosciences, 1∶15000), anti-mouse-HRP (Jackson ImmunoResearch, 1∶10000).

Human embryonic kidney 293T cell culture and transfection

Human embryonic kidney (HEK) 293T cells (ATCC CRL-11268) were cultured in the DMEM (Invitrogen) with 10% fetal bovine serum and Pen-Strep at 37°C in 5% CO2/air atmosphere. A CaPO4-based procedure was used to transfect the cells for RNAi experiments. 0.5 µg of cDNA vectors and 0.02 µg of silencing vectors were used for 2×105 cells. The culture medium was changed 6 hours post-transfection and protein was harvested 48 h later.

Supporting Information

Figure S1.

cAMP levels are not changed by modulation of RGS2 expression in primary striatal neurons. Primary striatal neurons were infected with an RGS2-encoding construct as in Fig. 3 (A) or an RGS2 silencing construct as in Fig. 4A (B). After 2 weeks in culture, levels of cAMP were measured in basal conditions and after stimulation with 10 µM SKF-82958 for 15 min. Values are presented as mean±SEM, n = 3. NS – non significant.


Figure S2.

RGS2 silencing effect on ERK2 phosphorylation in neurons expressing wild type htt. Primary striatal neurons were infected with htt171-18Q expression and RGS2 silencing vectors as described in Fig. 4B. After 2.5 weeks in culture, levels of ERK2 phosphorylation were measured by immunoblot. Data are presented as mean±SEM, n = 5, normalized to htt171-82Q+shGFP control. ** p<0.01.


Figure S3.

RGS2 silencing effect on Akt phosphorylation in neurons expressing mutant htt. Primary striatal neurons were infected with htt171-82Q expression and RGS2 silencing vectors as described in Fig. 4B. After 2.5 weeks in culture, levels of Akt phosphorylation were measured by immunoblot. Data are presented as mean±SEM, n = 6, normalized to htt171-82Q+shGFP control.



We thank Maria De Fatima Rey for the preparation of viral vectors, and Meredith Dixon, Marc Forrest, Liliane Glauser and Lely Feletti for the preparation of primary neuronal cultures. Thanks also to Aurelie Pala and Anne Planche for help with preliminary experiments.

Author Contributions

Conceived and designed the experiments: OG TS RL-C. Performed the experiments: TS OG. Analyzed the data: TS OG RL-C. Contributed reagents/materials/analysis tools: TS OG RL-C. Wrote the paper: TS RL-C OG.


  1. 1. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971–983.
  2. 2. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537–548.
  3. 3. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990–1993.
  4. 4. Truant R, Atwal RS, Burtnik A (2007) Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Prog Neurobiol Nov; 83: 211–227.
  5. 5. Luthi-Carter R (2007) Huntington’s and other polyglutamine diseases: many effects of single gene mutations. Drug Discovery Today: Disease Mechanisms. pp. 111–119.
  6. 6. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11: 1911–1926.
  7. 7. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9: 1259–1271.
  8. 8. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, et al. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96: 743–757.
  9. 9. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845–1861.
  10. 10. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965–977.
  11. 11. Luthi-Carter R, Cha CJJ (2003) Mechanisms of transcriptional dysregulation in Huntington's disease. Clinical neuroscience research 3: 165–177.
  12. 12. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233–238.
  13. 13. Crittenden JR, Dunn DE, Merali FI, Woodman B, Yim M, et al. (2010) CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Hum Mol Genet 19: 1756–1765.
  14. 14. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23: 9418–9427.
  15. 15. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 105: 15564–15569.
  16. 16. Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, et al. (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 16: 1164–1175.
  17. 17. Heximer SP, Srinivasa SP, Bernstein LS, Bernard JL, Linder ME, et al. (1999) G protein selectivity is a determinant of RGS2 function. J Biol Chem 274: 34253–34259.
  18. 18. Ingi T, Krumins AM, Chidiac P, Brothers GM, Chung S, et al. (1998) Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. J Neurosci 18: 7178–7188.
  19. 19. Han J, Mark MD, Li X, Xie M, Waka S, et al. (2006) RGS2 determines short-term synaptic plasticity in hippocampal neurons by regulating Gi/o-mediated inhibition of presynaptic Ca2+ channels. Neuron 51: 575–586.
  20. 20. Salim S, Sinnarajah S, Kehrl JH, Dessauer CW (2003) Identification of RGS2 and type V adenylyl cyclase interaction sites. J Biol Chem 278: 15842–15849.
  21. 21. Sinnarajah S, Dessauer CW, Srikumar D, Chen J, Yuen J, et al. (2001) RGS2 regulates signal transduction in olfactory neurons by attenuating activation of adenylyl cyclase III. Nature 409: 1051–1055.
  22. 22. Anger T, Klintworth N, Stumpf C, Daniel WG, Mende U, et al. (2007) RGS protein specificity towards Gq- and Gi/o-mediated ERK 1/2 and Akt activation, in vitro. J Biochem Mol Biol 40: 899–910.
  23. 23. Runne H, Regulier E, Kuhn A, Zala D, Gokce O, et al. (2008) Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci 28: 9723–9731.
  24. 24. Kotter R (1994) Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 44: 163–196.
  25. 25. Paul S, Snyder GL, Yokakura H, Picciotto MR, Nairn AC, et al. (2000) The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J Neurosci 20: 5630–5638.
  26. 26. Paul S, Nairn AC, Wang P, Lombroso PJ (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 6: 34–42.
  27. 27. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051–1058.
  28. 28. Vargiu P, Morte B, Manzano J, Perez J, de Abajo R, et al. (2001) Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. Brain Res Mol Brain Res 94: 1–8.
  29. 29. Wennerberg K, Rossman KL, Der CJ (2005) The Ras superfamily at a glance. J Cell Sci 118: 843–846.
  30. 30. Spano D, Branchi I, Rosica A, Pirro MT, Riccio A, et al. (2004) Rhes is involved in striatal function. Mol Cell Biol 24: 5788–5796.
  31. 31. Errico F, Santini E, Migliarini S, Borgkvist A, Centonze D, et al. (2008) The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Mol Cell Neurosci 37: 335–345.
  32. 32. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 97: 6809–6814.
  33. 33. Spektor BS, Miller DW, Hollingsworth ZR, Kaneko YA, Solano SM, et al. (2002) Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res Mol Brain Res 102: 118–128.
  34. 34. Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, et al. (2004) RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol Chem 279: 21248–21256.
  35. 35. Joseph R, Dou D, Tsang W (1994) Molecular cloning of a novel mRNA (neuronatin) that is highly expressed in neonatal mammalian brain. Biochem Biophys Res Commun 201: 1227–1234.
  36. 36. Zheng S, Chou AH, Jimenez AL, Khodadadi O, Son S, et al. (2002) The fetal and neonatal brain protein neuronatin protects PC12 cells against certain types of toxic insult. Brain Res Dev Brain Res 136: 101–110.
  37. 37. Rudinskiy N, Kaneko Y, Beesen A, Gokce O, Régulier E, et al. (2009) Diminished hippocalcin expression in huntington's disease (HD) brain does not account for increased striatal neuron vulnerability as assessed in primary neuron models of HD.
  38. 38. Subramaniam S, Sixt KM, Barrow R, Snyder SH (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324: 1327–1330.
  39. 39. Song Y, Altarejos J, Goodarzi MO, Inoue H, Guo X, et al. (2010) CRTC3 links catecholamine signalling to energy balance. Nature 468: 933–939.
  40. 40. Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291: 2423–2428.
  41. 41. Sugars KL, Brown R, Cook LJ, Swartz J, Rubinsztein DC (2004) Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 279: 4988–4999.
  42. 42. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15: 273–285.
  43. 43. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, et al. (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20: 261–270.
  44. 44. Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 10: 1829–1845.
  45. 45. Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, et al. (2002) Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res 68: 716–729.
  46. 46. Gines S, Seong I, Fossale E, Ivanova E, Trettel F, et al. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Human Molecular Genetics 12: 497–508.
  47. 47. Obrietan K, Hoyt KR (2004) CRE-mediated transcription is increased in Huntington's disease transgenic mice. J Neurosci 24: 791–796.
  48. 48. Hetman M, Gozdz A (2004) Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem 271: 2050–2055.
  49. 49. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB (2004) Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem 271: 2060–2066.
  50. 50. Lievens JC, Woodman B, Mahal A, Bates GP (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 20: 638–648.
  51. 51. Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, et al. (2008) Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J 22: 1083–1093.
  52. 52. Inoue-Mochita M, Inoue T, Epstein DL, Blumer KJ, Rao PV (2009) RGS2-deficient mice exhibit decreased intraocular pressure and increased retinal ganglion cell survival. Mol Vis 15: 495–504.
  53. 53. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, et al. (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 111: 1259.
  54. 54. Zucker B, Luthi-Carter R, Kama JA, Dunah AW, Stern EA, et al. (2005) Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 14: 179–189.